Compared to DPP‐4 inhibitors, low‐affinity cardiac mitoKATP channel sulfonylureas were not associated with an increased risk of 3‐point MACE (weighted HR, 1.01; 95% CI, 0.96–1.06) or its individual components (Table 3), but were associated with a 2.58‐fold (95% CI, 2.24–2.98) higher risk of hypoglycaemia. The gene discussed is DPP4; the disease is Hypoglycemia.